Neos Therapeutics Financials

$257.9 M

Mkt cap, 16-Feb-2018
Net income (Q3, 2017)(16.3 M)
EBIT (Q3, 2017)(14 M)
Cash, 30-Sep-201743.4 M
EV280.5 M

Revenue/Financials

Income Statement

Annual

USDFY, 2015FY, 2016

Revenue

3.8 m9.2 m

Revenue growth, %

141%

Cost of goods sold

5.5 m11.4 m

Gross profit

(1.8 m)(2.3 m)

Gross profit Margin, %

(46%)(25%)

R&D expense

11.9 m12.2 m

General and administrative expense

7.5 m12.6 m

Operating expense total

19.4 m24.8 m

EBIT

(26.6 m)(76.4 m)

EBIT margin, %

(701%)(835%)

Interest expense

3.7 m6.9 m

Net Income

(30.8 m)(83.3 m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1.5 m221 k

Cost of goods sold

2.3 m1.7 m2.3 m4.6 m2.6 m2.4 m

R&D expense

2.1 m2.7 m2.3 m4.3 m2.9 m1.7 m3.7 m

General and administrative expense

1.7 m2.1 m3.6 m3.5 m3.1 m3.5 m3.3 m

Operating expense total

3.8 m4.8 m5.9 m7.8 m6.1 m5.3 m7 m

EBIT

(4.5 m)(7 m)(11.9 m)(24 m)(23.7 m)(15 m)(16.4 m)(14 m)

EBIT margin, %

(306%)(3156%)

Interest expense

884 k1 m961 k1.5 m2.1 m2.2 m2.4 m2.6 m

Net Income

(5.8 m)(9.4 m)(12.6 m)(26.5 m)(25.8 m)(17.1 m)(18.7 m)(16.3 m)

Balance Sheet

Annual

USDFY, 2015FY, 2016

Cash

90.8 m24.4 m

Accounts Receivable

1.2 m

Inventories

2.5 m5.8 m

Current Assets

98.2 m55.3 m

PP&E

5.1 m7.1 m

Total Assets

122.5 m80.1 m

Accounts Payable

4.8 m7.8 m

Short-term debt

8 m4.9 m

Current Liabilities

15.9 m21.6 m

Long-term debt

26.3 m58.6 m

Non-Current Liabilities

28.2 m60 m

Total Debt

34.2 m63.5 m

Total Liabilities

44.1 m81.7 m

Additional Paid-in Capital

195.3 m198.8 m

Retained Earnings

(116.8 m)(200.1 m)

Total Equity

78.4 m(1.5 m)

Debt to Equity Ratio

0.4 x-41 x

Debt to Assets Ratio

0.3 x0.8 x

Financial Leverage

1.6 x-51.8 x

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

25.6 m102.9 m42.4 m41.9 m43.5 m43.7 m57.4 m43.4 m

Inventories

1.7 m2.7 m2.5 m4.4 m5.7 m5.6 m6.1 m10 m

Current Assets

29.7 m106.4 m93.1 m91.9 m72 m74.7 m93.1 m87.9 m

PP&E

5.3 m5.2 m5.4 m6.8 m7 m7 m8.2 m

Total Assets

55.9 m131.1 m117.9 m117.7 m97.4 m99 m118.3 m113.2 m

Accounts Payable

1.3 m2.4 m3.5 m3.3 m7.8 m7 m8.3 m10.7 m

Short-term debt

5.8 m2.3 m1.7 m3.2 m7 m7 m6.9 m

Current Liabilities

7 m13.2 m17.9 m16.8 m21.4 m26 m30.6 m36.4 m

Long-term debt

31.2 m28.6 m31.8 m59 m59 m59 m

Non-Current Liabilities

37.6 m30.9 m33.5 m60.2 m60.1 m60.4 m62.4 m62.1 m

Total Debt

31.2 m34.4 m34.1 m1.7 m3.2 m66 m66 m65.9 m

Additional Paid-in Capital

5.1 m194.7 m195.9 m196.8 m197.8 m230 m261.4 m267 m

Retained Earnings

(98.1 m)(107.7 m)(129.4 m)(155.9 m)(181.7 m)(217.2 m)(235.9 m)(252.1 m)

Total Equity

(93 m)87 m66.4 m40.7 m15.9 m12.6 m25.3 m14.7 m

Debt to Equity Ratio

4.5 x

Debt to Assets Ratio

0.6 x

Financial Leverage

-0.6 x1.5 x1.8 x2.9 x6.1 x7.9 x4.7 x7.7 x

Cash Flow

Annual

USDFY, 2015FY, 2016

Net Income

(30.8 m)(83.3 m)

Accounts Receivable

(2.2 m)

Inventories

2.5 m(3.2 m)

Accounts Payable

4.8 m3 m

Cash From Operating Activities

(70.6 m)

Cash From Investing Activities

(19.3 m)

Cash From Financing Activities

23.6 m

Interest Paid

2.9 m

Free Cash Flow

(74.2 m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(5.8 m)(9.4 m)(12.6 m)(39.2 m)(65 m)(17.1 m)(35.8 m)(16.3 m)

Accounts Receivable

(2.8 m)(1.8 m)(360 k)(5.7 m)466 k

Inventories

1.7 m2.7 m19 k(1.9 m)(3.2 m)175 k(313 k)10 m

Accounts Payable

1.3 m2.4 m(1.4 m)(1.5 m)3 m(1.3 m)180 k10.7 m

Cash From Operating Activities

(13 m)(31.7 m)(50.8 m)(15.9 m)(22.3 m)

Cash From Investing Activities

(34.9 m)(41.4 m)(20 m)4.7 m(4.4 m)

Cash From Financing Activities

(451 k)24.2 m23.5 m30.6 m59.7 m

Interest Paid

687 k2.8 m2.8 m19 k2.2 m

Free Cash Flow

(13.7 m)(34.4 m)(53.9 m)(16.1 m)(24 m)

Ratios

USDY, 2017

EV/EBIT

-20 x

Debt/Equity

4.5 x

Debt/Assets

0.6 x

Financial Leverage

7.7 x
Report incorrect company information